Clinical Outcomes of Ceftazidime–Avibactam versus Ceftolozane–Tazobactam in Managing Pseudomonal Infections in Patients Undergoing Renal Replacement Therapy

The optimal doses of ceftazidime–avibactam (CZA) and ceftolozane–tazobactam (C/T) for treating multidrug-resistant (MDR) Pseudomonas aeruginosa (PSA) in patients utilizing renal replacement therapy (RRT) are not well established. Hence, the objective of this study is to evaluate the clinical outcome...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Wasim S. El Nekidy, Mooza Al Ali, Emna Abidi, Rania El Lababidi, Diaa Alrahmany, Islam M. Ghazi, Mohamad Mooty, Fadi Hijazi, Muriel Ghosn, Jihad Mallat
Formato:	Artigo
Idioma:	Inglês
Publicado em:	MDPI AG 2024-07-01
coleção:	Antibiotics
Assuntos:	ceftazidime–avibactam ceftolozane–tazobactam dialysis outcomes
Acesso em linha:	https://www.mdpi.com/2079-6382/13/8/699
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!